AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11074227 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20‐60 mg/day)
Number of subjects: 323
Study 11074227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50‐150 mg/day)
Number of subjects: 323
Study 11074227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 8823568 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (3 mg/100 ml) and 5-aminosalicylic acid (2 g/100 ml)
Number of subjects: 60
Study 8823568 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (3 mg/100 ml)
Number of subjects: 60
Study 8823568 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (2 g/100 ml)
Number of subjects: 60
Study 1316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily for 14 days)
Number of subjects: 63
Study 1316078 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX, 160/800 mg orally twice daily for 14 days)
Number of subjects: 63
Study 1316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg)
Number of subjects: 63
Study 1316078 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 63
Study 1316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 63
Study 31254631 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe sleep counseling during well child visits (WCVs)
Number of subjects: 0
Study 31254631 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal report of infant sleeping with a person or an object in sleep space
Number of subjects: 0
Study 28161208 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory Microscope (LM)
Number of subjects: 39
Study 28161208 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Microscope (HM)
Number of subjects: 39
Study 28161208 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Tablet (HT)
Number of subjects: 39
Study 28161208 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 26227101 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (400/500/100 μg)
Number of subjects: 88
Study 26227101 — intervention group
Group type: COMPARATOR
Intervention: FF/VI (400/100 μg)
Number of subjects: 88
Study 26227101 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI (500/100 μg)
Number of subjects: 88
Study 26227101 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI (250/100 μg)
Number of subjects: 88
Study 25610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 1 mg prostaglandin E2
Number of subjects: 39
Study 25610872 — intervention group
Group type: COMPARATOR
Intervention: Intracervical 0.5 mg prostaglandin E2
Number of subjects: 39
Study 25610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 21629206 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH/ACTH(4-10)
Number of subjects: 10
Study 21629206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19485284 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-chopping rotation and axial rotation techniques
Number of subjects: 654
Study 19485284 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial rotation technique
Number of subjects: 654
Study 19485284 — intervention group
Group type: COMPARATOR
Intervention: Quick chop technique
Number of subjects: 654
Study 17655633 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 62
Study 17655633 — intervention group
Group type: COMPARATOR
Intervention: Water-based lubricating gel
Number of subjects: 62
Study 15954909 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily for 2 months
Number of subjects: 78
Study 15954909 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg daily for 2 months
Number of subjects: 78
Study 15954909 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg daily for 2 months
Number of subjects: 78
Study 15954909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 12141378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group (HT)
Number of subjects: 24
Study 12141378 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group (NT)
Number of subjects: 24
Study 12141378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 10738352 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 1829
Study 10738352 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 1829
Study 10738352 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829
Study 10738352 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1829
Study 7763028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics monitored dose adaptation of MTX (group 2)
Number of subjects: 71
Study 7763028 — intervention group
Group type: COMPARATOR
Intervention: T10 protocol with dose adapted only to age (group 1)
Number of subjects: 71
Study 2325029 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine lavage with 2 g of cefotaxime in 1,000 mL of normal saline
Number of subjects: 100
Study 2325029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 1 g of cefotaxime after cord clamping followed by 1-g doses 6 and 12 hours later
Number of subjects: 100
Study 527268 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant cyclic chemotherapy
Number of subjects: 65
Study 527268 — intervention group
Group type: COMPARATOR
Intervention: Post-operative local radiation therapy
Number of subjects: 65
Study 31830632 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based artifact reduction algorithm (AAR)
Number of subjects: 0
Study 31830632 — intervention group
Group type: COMPARATOR
Intervention: Iterative reconstruction technique 2 (IR2)
Number of subjects: 0
Study 31830632 — intervention group
Group type: COMPARATOR
Intervention: Iterative reconstruction technique 1 (IR1)
Number of subjects: 0
Study 31830632 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR
Number of subjects: 0
Study 31348920 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block with methylenum coeruleum guided by ultrasound
Number of subjects: 87
Study 29239024 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump bypass surgery
Number of subjects: 2203
Study 29239024 — intervention group
Group type: COMPARATOR
Intervention: Off-pump bypass surgery
Number of subjects: 2203
Study 25554072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to increase fish intake
Number of subjects: 18
Study 22178145 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (Powerpoint presentation)
Number of subjects: 232
Study 22178145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 232
Study 21296519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 0
Study 21296519 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (internal standard)
Number of subjects: 0
Study 19336724 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% DL-alpha-tocopherol
Number of subjects: 0
Study 19336724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17088141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal spray (200 microg, once daily for 28 days)
Number of subjects: 327
Study 17088141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 15593225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (n = 10)
Number of subjects: 21
Study 15593225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study 11488165 — intervention group
Group type: EXPERIMENTAL
Intervention: LeukoNorm Cytochemia administered on 5 consecutive days starting with the day of oocyte retrieval (1 unit/10 kg dosage)
Number of subjects: 10
Study 11488165 — intervention group
Group type: COMPARATOR
Intervention: Normal treatment group (non-treatment group)
Number of subjects: 10
Study 9251876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 226
Study 9251876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 8431907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation treatment
Number of subjects: 114
Study 8431907 — intervention group
Group type: COMPARATOR
Intervention: Pelvic lymph node dissection
Number of subjects: 114
Study 8431907 — intervention group
Group type: EXPERIMENTAL
Intervention: Groin irradiation
Number of subjects: 114
Study 8431907 — intervention group
Group type: COMPARATOR
Intervention: Surgical dissection
Number of subjects: 114
Study 3119677 — intervention group
Group type: EXPERIMENTAL
Intervention: BW 942C (0.5 mg intravenous)
Number of subjects: 6
Study 3119677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28293779 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (50 mg/28 days)
Number of subjects: 121
Study 28293779 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 121
Study 28293779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 µg/day)
Number of subjects: 121
Study 26639352 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/dose, 2 doses, 24h between doses)
Number of subjects: 22
Study 26639352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24556825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor)
Number of subjects: 80
Study 24556825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23332478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully branded female packs
Number of subjects: 947
Study 23332478 — intervention group
Group type: EXPERIMENTAL
Intervention: Packs without descriptor words
Number of subjects: 947
Study 23332478 — intervention group
Group type: EXPERIMENTAL
Intervention: Packs without brand imagery or descriptors (plain packs)
Number of subjects: 947
Study 23332478 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded non-female brands
Number of subjects: 947
Study 20883060 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM) group
Number of subjects: 57
Study 20883060 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 57
Study 18418363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (12.5-75 mg/day)
Number of subjects: 86
Study 18418363 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-375 mg/day)
Number of subjects: 86
Study 18418363 — intervention group
Group type: COMPARATOR
Intervention: Comparison of paroxetine and venlafaxine
Number of subjects: 86
Study 16028343 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS-guided/ICD strategy (n = 79)
Number of subjects: 143
Study 16028343 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (n = 59)
Number of subjects: 143
Study 12461273 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐T magnetic resonance (MR) spectroscopy
Number of subjects: 14
Study 15539258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp oil
Number of subjects: 49
Study 15539258 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil
Number of subjects: 49
Study 15539258 — intervention group
Group type: EXPERIMENTAL
Intervention: Seed oil
Number of subjects: 49
Study 7861314 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible correction model
Number of subjects: 0
Study 7861314 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiographic measures of theories of bias
Number of subjects: 0
Study 1945967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG)
Number of subjects: 40
Study 1945967 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated skin cleanser
Number of subjects: 40
Study 7037757 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 46
Study 7037757 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 46
Study 30010101 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural therapy (6 sessions)
Number of subjects: 102
Study 30010101 — intervention group
Group type: COMPARATOR
Intervention: Control (stretching exercises only)
Number of subjects: 102
Study 26353843 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 25 mg plus PEG‐IFN/RBV
Number of subjects: 87
Study 26353843 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 50 mg plus PEG‐IFN/RBV
Number of subjects: 87
Study 26353843 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus PEG‐IFN/RBV
Number of subjects: 87
Study 26353843 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study 24433574 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (TT) patch delivering 300 mcg of testosterone/day
Number of subjects: 44
Study 24433574 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (Pl)
Number of subjects: 44
Study 21955035 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal glycohemoglobin A(1) concentration in the 2nd trimester was 9.2% for offspring born with asymmetric LGA.
Number of subjects: 19
Study 21955035 — intervention group
Group type: COMPARATOR
Intervention: Maternal glycohemoglobin A(1) concentration in the 2nd trimester was 7.5% for those born with symmetric LGA or AGA.
Number of subjects: 19
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminders
Number of subjects: 116
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one interactions
Number of subjects: 116
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliminating structural barriers
Number of subjects: 116
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: System-level changes
Number of subjects: 116
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational small-media interventions
Number of subjects: 116
Study 20726624 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids
Number of subjects: 116
Study 20726624 — intervention group
Group type: COMPARATOR
Intervention: No interventions tested
Number of subjects: 116
Study 17920738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned shell brace
Number of subjects: 10
Study 17920738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligned sleeve brace
Number of subjects: 10
Study 17920738 — intervention group
Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 10
Study 16190388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) 1.2 x 10(4) U/kg intravenously after induction, 0.6 x 10(4) U/kg UTI in priming solution, and 0.6 x 10(4) U/kg UTI 5 min before aortic decamping
Number of subjects: 24
Study 16190388 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 24
Study 12074692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase 120 kU/kg
Number of subjects: 31
Study 12074692 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 100 mg (bolus) + two-stage 90 min infusion
Number of subjects: 31
Study 12074692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase
Number of subjects: 31
Study 12074692 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 31
Study 10787398 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 330
Study 10787398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 8863926 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass-pollen allergen extract Alutard SQ
Number of subjects: 30
Study 8863926 — intervention group
Group type: COMPARATOR
Intervention: Histamine (placebo)
Number of subjects: 30
Study 1734364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin otic drops immediately after tympanostomy tube placement in the operating room only
Number of subjects: 0
Study 1734364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin otic drops for an additional 48 hours (4 drops in each ear, three times a day)
Number of subjects: 0
Study 1734364 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 6372437 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate 15 mg/kg twice daily for ten days
Number of subjects: 102
Study 6372437 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate 25 mg/kg twice daily for ten days
Number of subjects: 102
Study 30207000 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong (ZZKZ) capsule
Number of subjects: 392
Study 30207000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 28846002 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting daily hassles and parental depressive symptoms
Number of subjects: 402
Study 28846002 — intervention group
Group type: EXPERIMENTAL
Intervention: Household chaos (parent report)
Number of subjects: 402
Study 26215770 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupressure
Number of subjects: 108
Study 26215770 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure (sham acupressure)
Number of subjects: 108
Study 26215770 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 108
Study 23494526 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster treatment
Number of subjects: 118
Study 23494526 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 118
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: non-HDL cholesterol
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: apolipoprotein B
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL particle number
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL particle number
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: total HDL particle number
Number of subjects: 20000
Study 22539783 — intervention group
Group type: EXPERIMENTAL
Intervention: small HDL particle number
Number of subjects: 20000
Study 20150438 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for HER2
Number of subjects: 2123
Study 20150438 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for estrogen receptor (ER)
Number of subjects: 2123
Study 20150438 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for progesterone receptor (PgR)
Number of subjects: 2123
Study 20150438 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUA method of automated quantitative analysis for p53
Number of subjects: 2123
Study 18842455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held QoL diary (EORTC-QLQ-C30 and LC13 in A5 format)
Number of subjects: 57
Study 18842455 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of diary completion
Number of subjects: 57
Study 15917540 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 8
Study 15917540 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 8
Study 15917540 — intervention group
Group type: COMPARATOR
Intervention: Fasting and fed states
Number of subjects: 8
Study 12872741 — intervention group
Group type: COMPARATOR
Intervention: Randomly sampled residents
Number of subjects: 1140
Study 12872741 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients from dental clinics
Number of subjects: 1140
Study 10570376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional UVA1 phototherapy (50 J/cm²/day for 15 days)
Number of subjects: 120
Study 10570376 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 cold-light phototherapy (50 J/cm²/day for 15 days)
Number of subjects: 120
Study 10570376 — intervention group
Group type: COMPARATOR
Intervention: Combined UVA-UVB phototherapy (minimal erythema dose dependent for 15 days)
Number of subjects: 120
Study 8553408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 10 mg/d
Number of subjects: 193
Study 8553408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole 20 mg/d
Number of subjects: 193
Study 8553408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1846437 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed conjugated equine estrogen (0.625 mg)
Number of subjects: 3
Study 1846437 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate, norethindrone acetate, or d,l-norgestrel (doses providing protection against endometrial hyperplasia)
Number of subjects: 3
Study 6478427 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field (IF) radiotherapy
Number of subjects: 460
Study 6478427 — intervention group
Group type: COMPARATOR
Intervention: Extended field (EF) radiotherapy
Number of subjects: 460
Study 6478427 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after initial radiotherapy
Number of subjects: 460
Study 31712590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking two 150 ml glasses of water (Study 1 and Study 2)
Number of subjects: 68
Study 31712590 — intervention group
Group type: COMPARATOR
Intervention: Not drinking water (Study 1 and Study 2)
Number of subjects: 68
Study 29953439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbovigrastim
Number of subjects: 34
Study 29953439 — intervention group
Group type: COMPARATOR
Intervention: Control (physiologic saline)
Number of subjects: 34
Study 27110900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes of mindful breathing (MB)
Number of subjects: 60
Study 27110900 — intervention group
Group type: COMPARATOR
Intervention: Normal listening
Number of subjects: 60
Study 24277961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal clonidine 4 mcg/kg
Number of subjects: 60